-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 7, Youhe Pharmaceuticals, a wholly-owned subsidiary of Biocytometer, announced that its YH004 (4-1BB monoclonal antibody) Phase I Australia (numbered YH004002) clinical study has completed its first patient administration
This study is a classic multi-center, open-label, phase I dose-climbing study of YH004 single-agent and YH004 combined with anti-PD-1 monoclonal antibody.
Note: The original text has been deleted